Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Earnings of -$0.91 Per Share

Equities analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) to announce earnings of ($0.91) per share for the current quarter, Zacks reports. Three analysts have made estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($0.97). Atara Biotherapeutics also reported earnings per share of ($0.91) in the same quarter last year. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.45) per share for the current year, with EPS estimates ranging from ($3.78) to ($2.96). For the next year, analysts anticipate that the firm will post earnings of ($3.08) per share, with EPS estimates ranging from ($4.08) to ($2.51). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.11. Atara Biotherapeutics had a negative net margin of 1,451.79% and a negative return on equity of 113.94%. During the same period last year, the company posted ($0.86) earnings per share.

ATRA has been the topic of a number of research reports. Citigroup downgraded shares of Atara Biotherapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $15.00 to $8.00 in a report on Monday, May 9th. JPMorgan Chase & Co. cut their price target on shares of Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a report on Monday, March 28th. StockNews.com lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Canaccord Genuity Group cut their price target on shares of Atara Biotherapeutics from $78.00 to $67.00 in a report on Tuesday, March 1st. Finally, HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Atara Biotherapeutics in a report on Thursday, January 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $30.43.

NASDAQ ATRA opened at $5.13 on Thursday. The company’s 50 day simple moving average is $7.92 and its 200 day simple moving average is $12.85. Atara Biotherapeutics has a 12 month low of $4.84 and a 12 month high of $20.04. The company has a market capitalization of $479.17 million, a P/E ratio of -1.41 and a beta of 1.92.

Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Atara Biotherapeutics by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,189,899 shares of the biotechnology company’s stock valued at $76,085,000 after buying an additional 772,777 shares in the last quarter. Maverick Capital Ltd. increased its position in shares of Atara Biotherapeutics by 2.0% during the 3rd quarter. Maverick Capital Ltd. now owns 7,855,824 shares of the biotechnology company’s stock worth $140,619,000 after purchasing an additional 151,148 shares in the last quarter. BlackRock Inc. increased its position in shares of Atara Biotherapeutics by 2.2% during the 4th quarter. BlackRock Inc. now owns 7,816,552 shares of the biotechnology company’s stock worth $123,190,000 after purchasing an additional 164,961 shares in the last quarter. State Street Corp increased its position in shares of Atara Biotherapeutics by 45.1% during the 1st quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock worth $58,282,000 after purchasing an additional 1,949,418 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Atara Biotherapeutics by 99.0% during the 4th quarter. Point72 Asset Management L.P. now owns 4,613,700 shares of the biotechnology company’s stock worth $72,712,000 after purchasing an additional 2,295,400 shares in the last quarter.

About Atara Biotherapeutics (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Stories